In 2023, Germany led in Renin-Angiotensin System medicine sales at $2.35 billion, while South Korea followed at $1.52 billion, showcasing significant market presence. Canada's market saw a decline of 5.32%, contrasting with robust growth in nations like Australia at 4.94% and New Zealand at an impressive 18.78%. Iceland and South Korea also reported notable increases, by 5.25% and 5.02%, respectively. Over the last five years, the global Compound Annual Growth Rate (CAGR) highlighted steady growth in various key regions, excluding slight downturns in Canada and Belgium.
Future trends to watch include technological advancements in drug delivery, increasing healthcare access in emerging markets, and potential regulatory changes that could reshape competitive dynamics, presenting opportunities and challenges across different regions.
Top countries in Renin-Angiotensin System Medicine Sales by Country
| # | 10 Countries | Million US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 2,350 | 2023 | +1.73% | +3.46% | View data |
| 2 | 2 South Korea | 1,520 | 2023 | +3.93% | +5.02% | View data |
| 3 | 3 Canada | 608.4 | 2023 | -20.7% | -5.32% | View data |
| 4 | 4 Australia | 593.3 | 2023 | +2.13% | +4.94% | View data |
| 5 | 5 Croatia | 415.8 | 2023 | +2.92% | +2.38% | View data |
| 6 | 6 Belgium | 197.4 | 2023 | -1.69% | -0.32% | View data |
| 7 | 7 Czech Republic | 166.5 | 2023 | +4.06% | +4.55% | View data |
| 8 | 8 Chile | 106.4 | 2023 | +3.2% | +3.99% | View data |
| 9 | 9 Slovakia | 83.6 | 2023 | +1.7% | +3.23% | View data |
| 10 | 10 Sweden | 78.6 | 2023 | -0.63% | +4% | View data |
